MA54900A - Composés inhibiteurs de l'échangeur sodium-hydrogène 3 - Google Patents
Composés inhibiteurs de l'échangeur sodium-hydrogène 3Info
- Publication number
- MA54900A MA54900A MA054900A MA54900A MA54900A MA 54900 A MA54900 A MA 54900A MA 054900 A MA054900 A MA 054900A MA 54900 A MA54900 A MA 54900A MA 54900 A MA54900 A MA 54900A
- Authority
- MA
- Morocco
- Prior art keywords
- sodium
- inhibitor compounds
- hydrogen exchanger
- exchanger
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848652P | 2019-05-16 | 2019-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54900A true MA54900A (fr) | 2022-03-23 |
Family
ID=70919092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054900A MA54900A (fr) | 2019-05-16 | 2020-05-08 | Composés inhibiteurs de l'échangeur sodium-hydrogène 3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220213042A1 (fr) |
| EP (1) | EP3921308B1 (fr) |
| JP (1) | JP7194848B2 (fr) |
| KR (1) | KR20210151911A (fr) |
| CN (1) | CN113784956A (fr) |
| AU (1) | AU2020276204B2 (fr) |
| BR (1) | BR112021019936A2 (fr) |
| CA (1) | CA3136060A1 (fr) |
| EA (1) | EA202192414A1 (fr) |
| ES (1) | ES2927100T3 (fr) |
| IL (1) | IL287963A (fr) |
| MA (1) | MA54900A (fr) |
| MX (1) | MX2021013771A (fr) |
| WO (1) | WO2020231770A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10312963A1 (de) * | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| LT2384318T (lt) | 2008-12-31 | 2018-02-26 | Ardelyx, Inc. | Junginiai ir būdai, skirti nhe-medijuoto antiporto slopinimui, gydant sutrikimus, susijusius su skysčių kaupimusi ir druskų pertekliumi, bei virškinamojo trakto sutrikimus |
| EP3988120A1 (fr) * | 2013-04-12 | 2022-04-27 | Ardelyx, Inc. | Composés de liaison à nhe3 et procédés d'inhibition du transport de phosphate |
| KR102266143B1 (ko) | 2016-08-15 | 2021-06-17 | 일라이 릴리 앤드 캄파니 | NaPi-IIb 억제제로서 유용한 축합된 티오펜 유도체 |
-
2020
- 2020-05-08 JP JP2021565751A patent/JP7194848B2/ja active Active
- 2020-05-08 MA MA054900A patent/MA54900A/fr unknown
- 2020-05-08 AU AU2020276204A patent/AU2020276204B2/en active Active
- 2020-05-08 US US17/611,456 patent/US20220213042A1/en active Pending
- 2020-05-08 BR BR112021019936A patent/BR112021019936A2/pt unknown
- 2020-05-08 EP EP20729401.8A patent/EP3921308B1/fr active Active
- 2020-05-08 MX MX2021013771A patent/MX2021013771A/es unknown
- 2020-05-08 KR KR1020217036739A patent/KR20210151911A/ko active IP Right Grant
- 2020-05-08 CN CN202080033042.9A patent/CN113784956A/zh active Pending
- 2020-05-08 WO PCT/US2020/031999 patent/WO2020231770A1/fr active Application Filing
- 2020-05-08 CA CA3136060A patent/CA3136060A1/fr active Pending
- 2020-05-08 EA EA202192414A patent/EA202192414A1/ru unknown
- 2020-05-08 ES ES20729401T patent/ES2927100T3/es active Active
-
2021
- 2021-11-09 IL IL287963A patent/IL287963A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021013771A (es) | 2021-12-10 |
| JP7194848B2 (ja) | 2022-12-22 |
| US20220213042A1 (en) | 2022-07-07 |
| WO2020231770A1 (fr) | 2020-11-19 |
| EP3921308A1 (fr) | 2021-12-15 |
| CN113784956A (zh) | 2021-12-10 |
| AU2020276204B2 (en) | 2022-05-19 |
| BR112021019936A2 (pt) | 2021-12-07 |
| CA3136060A1 (fr) | 2020-11-19 |
| JP2022531438A (ja) | 2022-07-06 |
| IL287963A (en) | 2022-01-01 |
| ES2927100T3 (es) | 2022-11-02 |
| AU2020276204A1 (en) | 2021-10-07 |
| EP3921308B1 (fr) | 2022-08-03 |
| KR20210151911A (ko) | 2021-12-14 |
| EA202192414A1 (ru) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MA51669A (fr) | Composés | |
| MA49047A (fr) | Composés inhibiteurs d'ask1 et utilisations associées | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| UA42295S (uk) | Комп'ютер | |
| DE112020002807A5 (de) | Kühlvorrichtung | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA56021A (fr) | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 | |
| DK3745067T3 (da) | Varmeveksleranordning | |
| MA52937A (fr) | Composés inhibiteurs d'oga | |
| MA52935A (fr) | Composés inhibiteurs d'oga | |
| MA52936A (fr) | Composés inhibiteurs d'oga | |
| ES2967375T3 (es) | Línea de enfriamiento rápido | |
| DK3816557T3 (da) | Varmevekslerplade | |
| DK3795444T3 (da) | Arbejdstog | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| MA54900A (fr) | Composés inhibiteurs de l'échangeur sodium-hydrogène 3 | |
| DK3824240T3 (da) | Varmeveksler | |
| MA52938A (fr) | Composés inhibiteurs d'oga | |
| DK4065915T3 (da) | Varmeoverføringsplade | |
| DK3786559T3 (da) | Varmeveksleranordning |